CD38 as an immunomodulator in cancer

Yanli Li, Rui Yang, Limo Chen, Sufang Wu

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations

Abstract

CD38 is a transmembrane glycoprotein that is widely expressed in a variety of human tissues and cells, especially those in the immune system. CD38 protein was previously considered as a cell activation marker, and today monoclonal antibodies targeting CD38 have witnessed great achievements in multiple myeloma and promoted researchers to conduct research on other tumors. In this review, we provide a wide-ranging review of the biology and function of the human molecule outside the field of myeloma. We focus mainly on current research findings to summarize and update the findings gathered from diverse areas of study. Based on these findings, we attempt to extend the role of CD38 in the context of therapy of solid tumors and expand the role of the molecule from a simple marker to an immunomodulator.

Original languageEnglish (US)
Pages (from-to)2853-2861
Number of pages9
JournalFuture Oncology
Volume16
Issue number34
DOIs
StatePublished - Dec 2020

Keywords

  • CD38
  • biomarker
  • cancer immunotherapy
  • immune checkpoint therapy
  • immunomodulation
  • tumor microenvironment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'CD38 as an immunomodulator in cancer'. Together they form a unique fingerprint.

Cite this